BERKELEY, Calif., Nov. 9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office today issued two new patents to XOMA as part of the company’s expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta (IL-1 beta). The patents cover methods of treatment for Type 1 diabetes and certain cancers, including multiple myeloma, using XOMA 052 or other IL-1 beta antibodies with similar binding characteristics to XOMA 052.
